Suven Life Sciences Ltd. — Investor Relations & Filings
Suven Life Sciences Ltd. focuses on the discovery and development of novel therapeutic agents for Central Nervous System (CNS) disorders. The company specializes in New Chemical Entity (NCE) research, targeting unmet medical needs in conditions such as Alzheimer’s disease, schizophrenia, attention deficit hyperactivity disorder (ADHD), Huntington’s disease, Parkinson’s disease, and depression. Its clinical pipeline includes lead candidates like Masupirdine (SUVN-502) for cognitive impairment and Samelisant (SUVN-G3031) for narcolepsy. Suven utilizes an integrated drug discovery platform and maintains a significant global intellectual property portfolio. The organization provides drug discovery and development support services, leveraging expertise in medicinal chemistry and pharmacology to advance internal programs and collaborative research initiatives.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Please find attached News Release of our company | 2026-05-12 | English | |
| Press Release | 2026-05-12 | English | |
| Copy of Newspaper Publication | 2026-04-23 | English | |
| Price movement | 2026-04-08 | English | |
| Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-04-06 | English | |
| Trading Window | 2026-03-27 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 45207412 | Please find attached News Release of our company | 2026-05-12 | English | ||
| 45209254 | Press Release | 2026-05-12 | English | ||
| 42171737 | Copy of Newspaper Publication | 2026-04-23 | English | ||
| 42187106 | Price movement | 2026-04-08 | English | ||
| 42208254 | Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-04-06 | English | ||
| 42223422 | Trading Window | 2026-03-27 | English | ||
| 42197228 | Outcome of Board Meeting | 2026-03-06 | English | ||
| 42197303 | Allotment of Securities | 2026-03-06 | English | ||
| 42168398 | Copy of Newspaper Publication | 2026-02-19 | English | ||
| 42295958 | Price movement | 2026-02-06 | English | ||
| 42221508 | Monitoring Agency Report | 2026-02-03 | English | ||
| 42258219 | Copy of Newspaper Publication | 2026-01-30 | English | ||
| 42179002 | Appointment | 2026-01-29 | English | ||
| 42179326 | Resignation | 2026-01-29 | English | ||
| 42179815 | Outcome of Board Meeting | 2026-01-29 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
NEUROSCIENTIFIC BIOPHARMACEUTICALS LTD
Develops peptide-based therapeutics for neurodegenerative a…
|
NSB | AU | Professional, scientific and te… |
|
NEUROTECH INTERNATIONAL LIMITED
Clinical-stage biopharmaceutical company developing pediatr…
|
NTI | AU | Professional, scientific and te… |
|
NewAmsterdam Pharma Co N.V.
A clinical-stage biopharma developing therapies for metabol…
|
NAMS | NL | Professional, scientific and te… |
|
NEXALIS THERAPEUTICS LTD
Develops small molecule therapies for chronic inflammatory …
|
NX1 | AU | Professional, scientific and te… |
|
NextGen Biomed Ltd.
Develops novel therapeutic delivery systems and pain-free a…
|
NXGN | IL | Professional, scientific and te… |
|
NEXTURNBIOSCIENCE Co., LTD
Manufacturer of CNC automatic lathes and ultra-precision co…
|
089140 | KR | Professional, scientific and te… |
|
NFL Biosciences
Biopharmaceutical company developing botanical drug candida…
|
ALNFL | FR | Professional, scientific and te… |
|
NGeneBio Co., Ltd.
Develops NGS-based molecular diagnostic products and softwa…
|
354200 | KR | Professional, scientific and te… |
|
Nicox S.A.
Ophthalmology company developing therapies based on a nitri…
|
COX | FR | Professional, scientific and te… |
|
Nirvana Life Sciences Inc
Developing non-addictive psilocybin therapeutics to treat a…
|
NIRV | CA | Professional, scientific and te… |
Suven Life Sciences Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/61491/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=61491 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=61491 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=61491 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 61491}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Suven Life Sciences Ltd. (id: 61491)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.